arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Ginkgo Bioworks Holdings, Inc.

DNA
$7.96 ▼ -0.53 (-6.24%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
24 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ginkgo Bioworks Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $474.1M
Dividend Yield
Revenue Growth -59.7%
Op. Margin -366.5%
ROIC -16.1%
FCF / Share $-0.82
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.47M
↓ -59.7%
Net Income Profit after all expenses
$-82.59M
↑ +9.2%
Operating Margin Operating profit as % of sales
-366.5%
↓ -73.0% 0th
FCF / Share Free cash flow per share
$-0.82
↑ +25.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
14
Financial Health
0
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 24 quarters